![]() ![]() Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia. Hypoglycemia: Patients receiving Ozempic ® in combination with an insulin secretagogue (eg, sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.Pen-sharing poses a risk for transmission of blood-borne pathogens. Never Share an Ozempic ® Pen Between Patients: Ozempic ® pens must never be shared between patients, even if the needle is changed.Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. The effect of long-term glycemic control with semaglutide on diabetic retinopathy complications has not been studied. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. The absolute risk increase for diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline than among patients without a known history of diabetic retinopathy. Diabetic Retinopathy Complications: In a 2-year trial involving patients with type 2 diabetes and high cardiovascular risk, more events of diabetic retinopathy complications occurred in patients treated with Ozempic ® (3.0%) compared with placebo (1.8%). ![]() If pancreatitis is suspected, discontinue Ozempic ® promptly, and if pancreatitis is confirmed, do not restart. Observe patients carefully for signs and symptoms of pancreatitis (persistent severe abdominal pain, sometimes radiating to the back with or without vomiting).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |